"If you don't like bacteria, you're on the wrong planet"   Stewart Brand

 

Introduction

Exomnis is a young, R&D company based in Maastricht, the Netherlands. It was established in 2013 to pioneer the innovative utilisation of non-pathogenic species of Clostridium in medical and industrial applications. 

Our business strategy encompasses two pillars of research: 
  • The development of alternative, bacterium-based immunotherapy to target cancers and; 
  • probiotic-based disease prevention. 

Our profile, mission and strategy

Exomnis was established to pioneer the development of alternative, bacterium-based therapies to prevent, manage and treat cancer. Additionally, Exomnis is broadening its expertise in the area of commensal gut microbiota to modulate human’s health via local and systemic drug delivery.

Our flagship MSCTM (Modular Spore Chassis) technology employs the use of non-pathogenic spores of Clostridium species. It is individually tailored to promote cancer-protective mechanisms in patients’ intestines and/or deliver immunotherapeutics to the tumour site.

Exomnis Biotech’s mission is to deliver a fully optimised MSCTM technology that will contribute to the canon of immunotherapies to manage and prevent cancer, improve human health and susceptibility to gut diseases. 

Our strategy is to design, prototype and authenticate these approaches, followed by exclusive licensing to interested investors.